Skip to main content
. 2019 Aug 14;121(6):464–473. doi: 10.1038/s41416-019-0550-2

Fig. 6.

Fig. 6

Anti-tumour activity of doxorubicin and lurbinectedin in ML017 and ML017/ET xenografts. Mice bearing ML017 and ML017/ET were treated with doxorubicin 8 mg/kg q7dx2 or lurbinectedin 0,2 mg/kg q7dx3 (grey arrows). Doxorubicin was equally active against the two xenografts (a) while lurbinectedin was less effective in ML017/ET than in ML017 (b)